Literature DB >> 31418645

Pharmacists' attitudes toward dispensing naloxone and medications for opioid use disorder: A scoping review of the literature.

Andrew Muzyk1, Zachary P W Smothers2, Kathryn Collins3, Mark MacEachern4, Li-Tzy Wu5,6,7.   

Abstract

Background: Pharmacists are on the frontline caring for patients at risk of an opioid overdose and for patients with an opioid use disorder (OUD). Dispensing naloxone and medications for OUD and counseling patients about these medications are ways pharmacists can provide care. Key to pharmacists' involvement is their willingness to take on these practice responsibilities.
Methods: The purpose of this scoping review is to identify, evaluate, and summarize published literature describing pharmacists' attitudes toward naloxone and medications for OUD, i.e., methadone, buprenorphine, and naltrexone. All searches were performed on December 7, 2018, in 5 databases: Embase.com, PubMed.gov, Cumulative Index to Nursing and Allied Health Literature (CINAHL) via EBSCOhost, Cochrane Central Register of Controlled Trials via Wiley, and Clarivate Web of Science. Articles included original research conducted in the United States, described attitude-related language toward naloxone and medications for OUD, and pharmacists.
Results: A total of 1323 articles were retrieved, 7 were included. Five studies reported on pharmacists' attitudes toward naloxone dispensing, 1 study reported on attitudes toward naloxone, buprenorphine, and buprenorphine/naloxone, and 1 reported on attitudes toward buprenorphine/naloxone. Respondents were diverse, including pharmacists from different practice specialties. Studies found that pharmacists agreed with a naloxone standing order, believed that naloxone should be dispensed to individuals at risk of an opioid overdose, and were supportive of dispensing buprenorphine. A minority of pharmacists expressed negative attitudes. Barriers cited to implementation included education and training, workflow, and management support. Conclusions: Pharmacists were positive in their attitudes toward increased practice responsibilities for patients at risk of an opioid overdose or with an OUD. Pharmacists must receive education and training to be current in their understanding of OUD medications, and they must be supported in order to provide effective care to this patient population.

Entities:  

Keywords:  Attitudes; buprenorphine; naloxone; opioid; pharmacists; substance use

Mesh:

Substances:

Year:  2019        PMID: 31418645      PMCID: PMC6920531          DOI: 10.1080/08897077.2019.1616349

Source DB:  PubMed          Journal:  Subst Abus        ISSN: 0889-7077            Impact factor:   3.716


  19 in total

1.  Naloxone for Opioid Overdose and the Role of the Pharmacist.

Authors:  Yuliana Toderika; Shalonda Williams
Journal:  Consult Pharm       Date:  2018-02-01

2.  The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration.

Authors:  Alessandro Liberati; Douglas G Altman; Jennifer Tetzlaff; Cynthia Mulrow; Peter C Gøtzsche; John P A Ioannidis; Mike Clarke; P J Devereaux; Jos Kleijnen; David Moher
Journal:  Ann Intern Med       Date:  2009-07-20       Impact factor: 25.391

3.  Treatment of Opioid-Use Disorders.

Authors:  Marc A Schuckit
Journal:  N Engl J Med       Date:  2016-10-20       Impact factor: 91.245

Review 4.  ASHP Statement on the Pharmacist's Role in Substance Abuse Prevention, Education, and Assistance.

Authors: 
Journal:  Am J Health Syst Pharm       Date:  2016-05-01       Impact factor: 2.637

5.  Pharmacists' and technicians' perceptions and attitudes toward dispensing buprenorphine/ naloxone to patients with opioid dependence.

Authors:  Dennis W Raisch; Paul J Fudala; Andrew J Saxon; Robert Walsh; Paul Casadonte; Walter Ling; Bankole A Johnson; Usha Malkerneker; Patricia Ordorica; William O Williford; Mike R Sather
Journal:  J Am Pharm Assoc (2003)       Date:  2005 Jan-Feb

6.  Opinions and experiences of Indiana pharmacists and student pharmacists: the need for addiction and substance abuse education in the United States.

Authors:  Cody J Wenthur; Bethany S Cross; Veronica P Vernon; Jamie L Shelly; Brielle N Harth; Adam D Lienhoop; Nicholas R Madison; Matthew M Murawski
Journal:  Res Social Adm Pharm       Date:  2012-06-12

7.  Knowledge, attitudes and practices of pharmacists concerning prescription drug abuse.

Authors:  Lynn Lafferty; Tracy S Hunter; Wallace A Marsh
Journal:  J Psychoactive Drugs       Date:  2006-09

8.  The case for chronic disease management for addiction.

Authors:  Richard Saitz; Mary Jo Larson; Colleen Labelle; Jessica Richardson; Jeffrey H Samet
Journal:  J Addict Med       Date:  2008-06       Impact factor: 3.702

9.  The opioid overdose epidemic: opportunities for pharmacists.

Authors:  Li-Tzy Wu; Udi E Ghitza; Anne L Burns; Paolo Mannelli
Journal:  Subst Abuse Rehabil       Date:  2017-07-31

10.  Predicting pharmacy naloxone stocking and dispensing following a statewide standing order, Indiana 2016.

Authors:  B E Meyerson; J D Agley; A Davis; W Jayawardene; A Hoss; D J Shannon; P T Ryder; K Ritchie; R Gassman
Journal:  Drug Alcohol Depend       Date:  2018-04-26       Impact factor: 4.492

View more
  10 in total

1.  Limited access to pharmacy-based naloxone in West Virginia: Results from a statewide purchase trial.

Authors:  Robin A Pollini; Jenny E Ozga; Rebecca Joyce; Ziming Xuan; Alexander Y Walley
Journal:  Drug Alcohol Depend       Date:  2021-12-31       Impact factor: 4.492

2.  Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.

Authors:  Gerald Cochran; Julie Bruneau; Nicholas Cox; Adam J Gordon
Journal:  Subst Abus       Date:  2020       Impact factor: 3.716

3.  Prescribing Naloxone to High-Risk Patients in the Emergency Department: Is it Enough?

Authors:  Scott G Weiner; Jason A Hoppe
Journal:  Jt Comm J Qual Patient Saf       Date:  2021-04-04

4.  Nobody Wants to Be Narcan'd: A Pilot Qualitative Analysis of Drug Users' Perspectives on Naloxone.

Authors:  Jeffrey T Lai; Charlotte E Goldfine; Brittany P Chapman; Melissa M Taylor; Rochelle K Rosen; Stephanie P Carreiro; Kavita M Babu
Journal:  West J Emerg Med       Date:  2021-02-08

5.  Take-home naloxone programs for suspected opioid overdose in community settings: a scoping umbrella review.

Authors:  Amina Moustaqim-Barrette; Damon Dhillon; Justin Ng; Kristen Sundvick; Farihah Ali; Tara Elton-Marshall; Pamela Leece; Katherine Rittenbach; Max Ferguson; Jane A Buxton
Journal:  BMC Public Health       Date:  2021-03-26       Impact factor: 3.295

Review 6.  Perspectives of Stakeholders of Equitable Access to Community Naloxone Programs: A Literature Review.

Authors:  Lucas Martignetti; Winnie Sun
Journal:  Cureus       Date:  2022-01-20

7.  If we build it, will they come? Perspectives on pharmacy-based naloxone among family and friends of people who use opioids: a mixed methods study.

Authors:  Susannah Slocum; Jenny E Ozga; Rebecca Joyce; Alexander Y Walley; Robin A Pollini
Journal:  BMC Public Health       Date:  2022-04-13       Impact factor: 3.295

8.  Improving Uptake of Emergency Department-initiated Buprenorphine: Barriers and Solutions.

Authors:  Timothy D Kelly; Kathryn F Hawk; Elizabeth A Samuels; Reuben J Strayer; Jason A Hoppe
Journal:  West J Emerg Med       Date:  2022-07-11

9.  Associations between naloxone prescribing and opioid overdose among patients with acute and chronic pain conditions.

Authors:  Fares Qeadan; Erin Fanning Madden
Journal:  Addiction       Date:  2021-08-16       Impact factor: 7.256

Review 10.  Considering the Potential Benefits of Over-the-Counter Naloxone.

Authors:  Kirk E Evoy; Lucas G Hill; Corey S Davis
Journal:  Integr Pharm Res Pract       Date:  2021-02-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.